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-bindingprotcins;The S-100 protein family; Novel members of the 
EF-hand calcium-binding protein family in normal and 
transformed cells; Calcium-binding proteins in bacteria, fungi and 
invertebrates; Structure, function and evolution; Calcium fluxes, 
binding and metabolism; Calcium-dependent and phospholipid- 
binding proteins in health and disease. 
In the first section the members of the EF-hand homolog family 
are identified and characterized and thereby distinguished from 
several similar analogs. Undoubtedly future research will reveal 
additional EF-hand homolog subfamilies and functions in relation 
to Ca’+-signaling, This section also includes a survey of the Ca”- 
binding proteins of the EF-hand type, the annexin family and also 
describes a dye that can be used to probe the conformational 
features of Ca?‘-binding proteins. 
In section two, the S-100 protein family is discussed in detail, 
starting with an instructive biochemical and functional overview 
by Hilt and K&man. Interestingly, the S-100 proteins arc a group 
of small acidic Ca’+.binding proteins that are expressed 
specifically in various types of cells and hence may be involved in 
transducing the Ca2* signal in a cell-type dependent fashion, They 
may exert their effects by regulating the phosphorylation of 
specific effector proteins involved in signal-transduction, cell 
motility and cytokinesis, cellular differentiation. cell-cycle 
progression and inflammation. This section also lists in a Table 
the members of the S-100 protein family and proteins which have 
been shown to be synonyms or species homologs of any of the 
family members, Each of these proteins is briefly discussed. For 
example. MRPB and MRP14 are two Ca”+mbinding proteins 
expressed during myelopoiesis. Interestingly, MRP14 plasma 
levels are elevated in cystic fibrosis and a variety or other 
pathological conditions, MRPB is mainly expressed in chronic 
inflammation like rheumatoid arthritis. 
In section three, novel Ca”-binding proteins of the EF.hand 
protein family arediscussed in relation to normal and transformed 
cells. Non-mu& a-actinin is an EFmhand Ca”-binding protein, 
likely toassist thesarcomeric unit to withstand the force generated 
by the actin-myosin contraction. This protein may anchor actin 
filaments to the plasma membrane of non-muscle cells. ar-Actinin 
contains two EF-hand structures close to the carboxyl-terminals 
and is involved in the reorganization of the cytoskeleton, which 
is of importance for cellular processes such as motility, 
cytokinesis, phagocytosis and secretion. It is of interest that ,& 
crystallin, which is a Ca*‘mbinding protein of the eye lens, loses its 
ability to bind Cd” with age, a phenomenon likely to take place 
also in cataract, 
Section four gives a detailed account for the Ca*+-binding 
proteins in bacteria, fungi and invertebrates. Of special interest is 
the Ca’+-binding site of the D-galactose/D-glucose-binding protein 
of Gram-negative bacteria as well as the discussion about a novel 
Ca2’-binding protein encoded in the shaker locus of Drosophila. 
In section five, the Ca”+-binding sites of various ion-channels 
arc discussed. It is evident that four Na’ channel al polypeptides 
and one dihydropyridine-sensitive Ca’+&annel al polypcptide 
have putative EF-hand type Ca”-binding sites near their 
carboxyl-terminals. It is suggested that voltage-gated Na+- 
channels and Ca-“-channels, but not K+.channels, can bind Ca*+ 
with portions of their internal sequences. In an interesting chapter 
by Erne et al., alterations in cellular Ca*’ handling is discussed in 
relation to hypertension and human cardiac hyperthrophy. It is 
suggested that abnormalities of Ca” metabolism are involved in 
the pathogenesis of established human hypertension. Direct 
comparison of Cal’ channels in vascular cells. from a neonatal 
spontaneous hypertensive versus normotensivc rat strain, showed 
an enhanced probability for an openhlg and larger Ca*’ currents 
of the sustained type in genetic hypertension. In addition, the free 
cytoplasmic Ca” concentration is elevated at rest in localized 
regions of vascular muscle cells from spontaneously hypertensive 
rats. These findingS were confirmed by confocal laser scan 
microscopy, indicating a subsarcolemmal increase in cytoplasmic 
free Ca*’ in the vascular muscle cell. 
Section six deals with the Ca2’-dependent and phospholipid- 
binding prcteins in health and disease. This section is devoted to 
the diversity in the annexin family, anncxin 1 and its biochemical 
properties and as well to a more clinical oriented chapter 
concerning the cnti.infIammatory activity of human recombinant 
lipoconin 1. 
Despite rhe fact that this book does not present a number of 
novel data and new concepts, it is of interest to all those who are 
engaged in the field of Cd’+-signaling research. The rapid progress 
made in terms of identification of novel Ca2+-binding proteins is 
not always parallelled by assigning them a function and 
consequently future research is needed 10 establish a role for the 
various Ca”-binding proteins not only in physiology but maybe 
more interestingly in pathophysiology. 
Per-Olof Berggren 
DNA Topobomcrascs in Cancer; Edited by M. Potmesil and K.W. Kohn; Oxford University Press Oxford; New York, 1991; 
xv + 331 pages. f65.00 
This informative book contains updated contributions horn 
work presented at international conferences on DNA 
topoisomerases in cancer chemotherapy held in 1986 and 1988 in 
New York City in association with the New York University 
Post-Graduate Medical School and the Rita and Stanley H. 
Kaplan Cancer Center. DNA topoisomerases are important 
cellular enzymes involved in many aspects of DNA function such 
as DNA replication. These enzymes change the superhelical 
structure of DNA and are classified as type I and type II according 
to their mechanism of action, Type I DNA topoisomerascs 
introduce transient single-strand DNA breaks, while type II DNA 
topoisomerases break both DNA strands to enable another duplex 
DNA segment LO pass through. The relaxation of DNA supercoils 
is one of the major catalytic functions of topoisomerases, although 
bacterial DNA topoisomerase II (bacterial DNA gyrase) 
introduces negative supercoils. Inhibitors of bacterial DNA gyrase 
such as nalidixic acid have been used therapeetically in the 
treatment of bacterial infections. DNA topoisomerases have been 
found to be a successful target site for the chemotherapy of certain 
cancers. The interaction between DNA topoisomerases and 
chemotherapeutic agents deveIoped for this purpose is examined 
in this book. 
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This book is organized into five main sections, which follow a of cancer or leukacmia and is associated with the overproduction 
good comprehensive introductory chapter. The first section of the integral membrane P-glycoprotein. The resistance 
(chapters 2-7) covers the basic aspects of the genetics and associated with DNA topoisomerases, however, appears to be 
biochemistry of prokaryotic and eukaryotic DNA topoisomerascs related to altered rquirsments of the topoisomerase nzymes and 
I and II, This section includes an examination in chapter 6 of is denoted as atMDR where ‘at’ is altered topoisomerase (chapter 
inhibitors of bacterial DNA gyrase such as the ctoposide VP-16, 21). Finally, the fifth section (chapters 23-25) deals with the 
which may offer a new approach to antitrypanosomal development and clinical use of topoisomerase inhibitors. These 
chemotherapy. The use of yeast permeability mutants as a genetic are used in the chemotherapy of patients with locally advaneed or 
system that facilitates the study of antilumour drugs such as metastatic olon cancer. It has been found that two derivatives of 
camptothecin, etoposides and teniposides targeted at DNA camptothecin, 9-amino-ZO(RS) and 10,l l-methylene-dioxy- 
topoisomerases is discussed in chapter 7. Purified yeast DNA 20(RS) give long-term disease-free remissions and are of low 
topoisomerases I and II are similar to their mammalian toxicity (chapter 24). They also appear lo by-pass the problem of 
counterparts in their interaction with these antitumour agents. cellular resistance mechanism in cancer cells. 
The second section of this book (chapters t-15) examines 
inhibitors of topoisomerasc I, including the natural product 
campothecin. This ia followed by a third section on inhibitors of 
topoisomerase II (chapters 16-19) The modification of the effects 
of topoisomerase inhibitors by the presence of other DNA binders 
such as polyamines is alo considered. The clinical problem of the 
resistance of cancer cell topoisomerases to the drugs against them 
is the theme of the fourth section (chapters 20-22). Multidrug 
resistance (MDR) is a particularly serious problem in many types 
This comprehensive volume deals in depth with a wide range of 
topics relating to DNA topoisomcrase with particular emphasis 
on the relationship to cancer chemotherapy. The individual 
chapters are well documented and there is an adquate index. This 
book will be of great use as a source of both background reading 
and detailed material on this important subject area where cell 
biology and enzymology advance cancer therapies. 
Helen Wiseman 
New Drugs for Asthma Therapy (Agents and Actions supplements, vol 34); Edited by G.P. Anderson, I.D. Chapman and 
J. Morley; Birckhauser-Verlag; BaseUBoston/Berlin, 1991; x + 548 pages, Sw.Fr.148.00 
This book conslitutes the proceedings of an IUPHAR satellite 
symposium entitled ‘New Drugs for Asthma’ organ&d by the 
editors, Anderson, Chapman and Morley, in 1990. The title is 
somewhat misleading since the majority of papers discuss the 
pharmacology of compounds under early investigation by various 
pharmaceutical companies. Furthermore, approximately 25% of 
the papers do not discuss any therapy for asthma, potential or 
otherwise, but focus on the use of animal preparations, usually 
guinea-pigs, to evaluate novel therapies. 
The book is divided into four sections, the first being devoted 
to bronchodilator drugs. Three papers review recent advances in 
the area of &adrenoceptor agonists, which have led to the 
development of two long-acting compounds, salmeterol and 
formoterol, and the terbutaline pro-drug, bambuterol. These 
agents clearly provide the standard against which any novel 
brocchodilator agent will have to be astissed. Furthermore, 
evidence suggests that the new, long-acting &adrcnoceptor 
agonist, salmeterol, may possess clinically useful anti- 
inflammatory actions, which the short-acting compounds do no. 
Against this background, the other papers in the section address 
the therapeutic potential of selective phosphodiesterase inhibitors, 
muscarinic agonists and potassium channel opening agents. 
Unfortunately, few of these agents have been extensively evaluated 
in man, and their true therapeutic potential remains unclear. 
The next two sections of this book are devoted to ‘Inhibitors of 
Allergic Mediators as Targets’ and ‘Prophylactic Anti-Asthmatic 
Drugs’, respectively, They contain a series of papers which 
describe different approaches aimed at either preventing the 
generation and release of pharmacological mediators, or blockiag 
the action of specific mediators. One highlight in this section is 
data from clinical studies with the thromboxane receptor 
antagonist, GR32191. It appears to demonstrate that throm- 
boxane receptor activation is not important in asthmatic 
bronchoconstriction. The rest of Ihe papers in this section describe 
the clinical and animal pharmacology of leukotriene receptor 
antagonists and inhibitors of lcukotriene synthesis, and the 
evaluation of a number of PAF receptor antagonists, anti- 
histamines and a range of agents of undefined mechanism. which 
modify various aspects of allergic reactions in sensitised animals. 
Notable omissions from these sections are papers on the 
pharmacology of tachykinin antagonists, an equally valid 
approach to a specific inhibitor of a putative allergic mediator, and 
an overview of the pharmacology ofglucocorticoids, agents which 
currently account for the majority of prophylactic therapy in 
asthma. 
The remainder of the book, in a se&on entitled ‘New 
approaches to Anti-Asthma Drug Deteelinn’, is a collection cf 
papers outlining methods of evaluating prospective therapies in 
animal preparations, The highlight of this section is a paper 
describing studies on the expression of the leukocyte adhesion 
molecules ICAM- and ELAM-1 during the response of sensitisecl 
primates to allergen, and the cffeet of antisera to these molecules 
on inflammatory cell recruitment and bronchial hyperreactivity. 
In this paper the case is made for an inhibitor of ICAM- as a 
therapy for asthma. 
In conclusion, this book may be of interest to those engaged in 
or cnterir:g the area of asthma research. However, the price seems 
rather high for a book which is already two years old. Therefore, 
I suspect more copies will be found in libraries than in personal 
dcXii0ilS. 
C.J. Whelan 
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